Long-Acting Injectable HIV Therapy Outcomes Among Persons With HIV Who Have Adherence Challenges to Oral Antiretroviral Therapy.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 40096545.
- Also identified by DOI 10.1093/cid/ciaf120 and PMC identifier 12497944.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Long-acting injectable cabotegravir/rilpivirine (LAI-CAB/RPV) may improve outcomes among persons with human immunodeficiency virus (PWH) with adherence difficulties to oral therapy. In this real-world observational study, over 85% of PWH remained on therapy and virally suppressed 48 weeks after initiating LAI-CAB/RPV. Providers should consider LAI therapy among PWH with adherence difficulties.
Medical subject headings
- HIV Infections
- Rilpivirine
- Anti-HIV Agents
- Medication Adherence
- Pyridones